|
|
Vol. 16.13 – 18 July, 2025
|
|
|
|
|
|
|
|
Glutamine depletion reduced forkhead box protein M1 transcriptional occupancy on the promoter of FGF8, a known mediator of prostate adenocarcinoma castration resistance. [Cancer Research]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers created an urinary large extracellular vesicles-centric proteomic approach for early prostate cancer identification.
[Analytical Chemistry]
|
|
|
|
|
|
Scientists investigated androgen receptor involvement in pain sensitivity and sex differences in pain perception. Manipulating androgen signaling in sensory neurons may offer a promising approach to managing mechanical pain.
[Pain]
|
|
|
|
|
|
This retrospective cohort study of 80,144 men from the Finnish Randomized Study of Screening for Prostate Cancer (PC), with a median follow-up of 18.0 years, compared determinants of low-risk PC with determinants of high-risk PC.
[International Journal of Cancer]
|
|
|
|
|
|
Investigators suggested that S100A6 may serve as a molecular marker or therapeutic target associated with castration resistance in prostate cancer, providing new insights into the molecular basis of this disease.
[Scientific Reports]
|
|
|
|
|
|
PSMA3-AS1 knockdown increased the level of miR-29a-3p and reduced the physiological activity of cancer cells. Therefore, regulating the expression of the PSMA3-AS1/miR-29a-3p axis could influence prostate adenocarcinoma development. [Hereditas]
|
|
|
|
|
|
|
|
The authors synthesize current findings on the role of copper and cuproptosis in prostate cancer, focusing on the mechanisms underlying cuproptosis, the identification of key biomarkers, and the therapeutic potential of copper complexes and ionophores.
[Cancer Biology & Therapy]
|
|
|
|
|
|
Scientists evaluate recent evidence on the utility of multiparametric MRI, prostate-specific membrane antigen PET, and their combined application for accurately delineating the intraprostatic gross tumor volume in patients with primary localized and locally advanced prostate cancer. [Current Opinion in Urology]
|
|
|
|
|
|
|
|
Trethera Corporation announced that the US FDA has granted Fast Track designation for its novel drug, TRE-515, in the treatment of prostate cancer. [Trethera Corporation]
|
|
|
|
|
|
|
|
August 19-21, 2025 Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
Imperial College London – London, England, United Kingdom
|
|
|
|
|
|
|
The Chinese Institutes for Medical Research (CIMR), Beijing – Beijing, China
|
|
|
|
|
|
|
Monash University – Melbourne, Australia
|
|
|
|
|
|
|
Indiana University – Bloomington, Indiana, United States
|
|
|
|
|
|
|
University of Glasgow – Glasgow, Scotland, United Kingdom
|
|
|
|
|
|